Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

被引：9

作者：

Hamid, O. ^{[1
]}

Puzanov, I. ^{[2
]}

Dummer, R. ^{[3
]}

Schachter, J. ^{[4
]}

Daud, A. ^{[5
]}

Schadendorf, D. ^{[6
]}

Blank, C. ^{[7
]}

Cranmer, L. D. ^{[8
,9
]}

Robert, C. ^{[10
,11
]}

Pavlick, A. C. ^{[12
]}

Gonzalez, R. ^{[13
]}

Hodi, F. S. ^{[14
]}

Ascierto, P. A. ^{[15
]}

Salama, A. ^{[16
]}

Margolin, K. A. ^{[17
]}

Gangadhar, T. C. ^{[18
]}

Wei, Z. ^{[19
]}

Ebbinghaus, S. W. ^{[19
]}

Ibrahim, N. ^{[19
]}

Ribas, A. ^{[20
]}

机构：

[1] Angeles Clin & Res Inst, Melanoma & Skin Canc Ctr, Los Angeles, CA USA

[2] Vanderbilt Ingram Canc Ctr, Hematol Oncol, Nashville, TN USA

[3] Univ Zurich, Dermatol, Zurich, Switzerland

[4] Sheba Canc Res Ctr, Ella Inst Melanoma, Oncol, Tel Hashomer, Israel

[5] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA

[6] Univ Hosp Essen, Dermatol, Essen, Germany

[7] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands

[8] Univ Washington, Med, Seattle, WA 98195 USA

[9] Seattle Canc Care Alliance, Seattle, WA USA

[10] Gustave Roussy, Dermatol, Villejuif, France

[11] Univ Paris Sud, Villejuif, France

[12] NYU, Inst Canc, Med, New York, NY USA

[13] Univ Colorado Denver, Med, Aurora, CO USA

[14] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[15] Fdn Pascale, IRCCS, Ist Nazl Tumori, Unit Melanoma Canc Immunotherapy & Innovat Therap, Naples, Italy

[16] Duke Univ, Med, Durham, NC USA

[17] City Hope Natl Med Ctr, Med Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA

[18] Univ Penn, Abramson Canc Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA

[19] Merck & Co Inc, Clin Res, Kenilworth, NJ USA

[20] Univ Calif Los Angeles, Med, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1107O

引用

页数：1